Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

3.51
+0.11003.24%
Post-market: 3.50-0.0097-0.28%17:49 EDT
Volume:1.47M
Turnover:5.08M
Market Cap:431.82M
PE:-3.86
High:3.53
Open:3.48
Low:3.36
Close:3.40
52wk High:5.17
52wk Low:1.69
Shares:123.03M
Float Shares:94.52M
Volume Ratio:0.78
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9085
EPS(LYR):-1.2666
ROE:-48.14%
ROA:-19.25%
PB:1.75
PE(LYR):-2.77

Loading ...

C4 Therapeutics says cemsidomide posts 53% response rate in Phase 1 relapsed/refractory multiple myeloma trial at 100 µg dose

Reuters
·
Jun 11

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

GlobeNewswire
·
Jun 11

C4 Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jun 02

Analysts Conflicted on These Healthcare Names: GlaxoSmithKline (GB:GSK) and C4 Therapeutics (CCCC)

TIPRANKS
·
May 30

BMS's Phase III Multiple Myeloma Data Impresses, Boosting C4 Therapeutics Shares

Deep News
·
May 30

C4 Therapeutics jumps after Bristol Myers myeloma data

TIPRANKS
·
May 29

CCCC AGM to Vote on RMB99 Billion Securitization, Capital Structure Changes

TIPRANKS
·
May 29

CCCC Sets Up RMB1 Billion Transportation Information Technology Fund as Connected Transaction

TIPRANKS
·
May 28

C4 Therapeutics joins TD Cowen Oncology Innovation Summit fireside chat

Reuters
·
May 20

C4 Therapeutics to Participate in Upcoming Conferences

GlobeNewswire
·
May 20

C4 Therapeutics grants new hire stock options for 85,480 shares under Nasdaq rule

Reuters
·
May 19

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 19

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 19

C4 Therapeutics Realigns Finance Leadership After Officer Departure

TIPRANKS
·
May 16

C4 Therapeutics names CFO Kendra Adams principal accounting officer, effective May 15

Reuters
·
May 16

C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns

Simply Wall St.
·
May 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 13

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

TIPRANKS
·
May 12

C4 Therapeutics publishes corporate presentation on targeted protein degradation pipeline, cemsidomide focus

Reuters
·
May 12